# Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers

> **NCT01710605** · PHASE3 · UNKNOWN · sponsor: **Institut Curie** · enrollment: 800 (actual)

## Conditions studied

- Ductal Infiltrating Metastatic Breast Cancer
- Hormone-receptors Positive Breast Cancer

## Interventions

- **BIOLOGICAL:** Circulating tumor cells counting at baseline

## Key facts

- **NCT ID:** NCT01710605
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-02
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2018-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01710605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01710605, "Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01710605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*